Clinical trials: PSA Failure
Prostate Cancer
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
The purpose of this research study is to determine if an investigational drug called Exisulind will extend the "off-treatment" period of patients receiving Intermittent Androgen Suppression (ADT).
- Trial name
- NCT00283803
- Testing
- Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body.
- Conditions
- Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis
- Trial name
- SOAR (NCT03796767)
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Prostatic Neoplasms, Prostate Neoplasms
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
This is a prospective, open-label, randomized, cross-over, pilot study of reprogramming therapy in patients with recurrent PCa based on rising PSA only.
- Conditions
- Prostatic Neoplasms, Prostate Neoplasms, Prostate Cancer
- Trial name
- NCT03572387
- Testing
- 5-Azacitidine, all trans retinoic acid, Lupron
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Sulforaphane in Treating Patients With Recurrent Prostate Cancer
This phase II trial studies how well sulforaphane works in treating patients with recurrent prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.
- Trial name
- NCT01228084
- Testing
- Sulforaphane, Laboratory biomarker analysis, Pharmacological study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
This phase II trial evaluates Fluorine-18 radiohybrid prostate-specific membrane antigen (18F- rhPSMA)-7.3 positron emission tomography (PET)/computed tomography (CT) scans with and without furosemide for the reduction of bladder…
- Trial name
- NCT05779943
- Testing
- Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Prostate Cancer, Prostatic Neoplasm
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new prostate-specific membrane antigen (PSMA) drug makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent
- Trial name
- NCT03389451
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Michael Graham PhD, MD
Prostate Adenocarcinoma, PSA Progression
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing participants with prostate cancer that has come…
- Conditions
- Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma
- Trial name
- NCT03698370
- Testing
- Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Andrei Iagaru
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 in BCR
The current study aimed at evaluating the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Trial name
- GuidePath (NCT04838613)
- Testing
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Prostate Cancer
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
- Trial name
- IAS (NCT00223665)
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Washington
Prostate Cancer
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
- Trial name
- NCT06604442
- Testing
- flotufolastat (18F), piflufolastat (18F)
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- Blue Earth Diagnostics
Prostate Cancer, Prostate Adenocarcinoma
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
- Trial name
- NCT03396874
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 1,435 people
- Sponsor
- University of Michigan
Prostate Adenocarcinoma, PSA Failure
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan.
- Conditions
- Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
- Trial name
- NCT02673151
- Testing
- Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Andrei Iagaru
Cancer of Prostate
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Obesity and metabolic syndrome are prevalent among prostate cancer patients. Having an elevated insulin level in the blood is associated with a shorter median time to cancer progression and median overall survival in patients…
- Trial name
- BIMET-1 (NCT02614859)
- Testing
- Observation and Bicalutamide, Metformin and Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Trial name
- CONDOR (NCT03739684)
- Testing
- 18F-DCFPyL, PET/CT Imaging
- Where
- 14 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- Progenics Pharmaceuticals, Inc.